Monoclonal antibody biosimilars are highly similar, cost-effective alternatives to expensive biologic drugs like Herceptin and Rituxan. Approved for cancer and autoimmune conditions, they offer the same safety and effectiveness at a fraction of the cost-with billions in savings projected by 2028.